Catalysts for Kyowa Kirin Co Ltd
7 tracked
Apr 30, 2026
phase 1 completion
Kyowa Kirin Co Ltd — brentuximab vedotin (Phase I Trial Completion)
brentuximab vedotin
→
Apr 29, 2026
phase 2 initiation
Kyowa Kirin Co Ltd — KK-4277 (Phase II Trial Initiation)
KK-4277
→
Feb 19, 2026
approval
POTELIGEO (MOGAMULIZUMAB-KPKC) — FDA approval
mogamulizumab
→
Jan 21, 2025
approval
POTELIGEO (MOGAMULIZUMAB-KPKC) — FDA approval
mogamulizumab
→
Mar 30, 2022
approval
POTELIGEO (MOGAMULIZUMAB-KPKC) — FDA approval
mogamulizumab
→
Jul 8, 2021
approval
POTELIGEO (MOGAMULIZUMAB-KPKC) — FDA approval
mogamulizumab
→
Aug 8, 2018
approval
POTELIGEO (MOGAMULIZUMAB-KPKC) — FDA approval
mogamulizumab
→